James N. Topper
James N. Topper's purchase track record
How the stock did after each of James N. Topper's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/8/2025 | NAMS | $47K | +42.5% | +22.6% | +4.6% |
| 8/11/2025 | NAMS | $11K | +59.9% | +43.6% | +9.3% |
| 6/24/2025 | NAMS | $69K | +45.0% | +95.4% | +13.4% |
| 6/16/2025 | NAMS | $167K | +22.1% | +79.0% | +13.0% |
| 5/21/2025 | PHAT | $15K | +172.6% | +279.2% | +13.7% |
| 5/9/2025 | PHAT | $177K | +210.2% | +322.0% | +18.9% |
| 3/26/2025 | NAMS | $26K | -18.8% | +18.6% | +16.2% |
| 3/4/2025 | NAMS | $84K | -13.1% | +14.6% | +11.0% |
| 3/26/2024 | NAMS | $181K | -13.4% | -31.6% | +10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
Transaction History
| PHAT | ▲ Buy | Grant | 24,122 | $0 | 5/19/2026 | View on chart |
| NAMS | ▲ Buy | Open Market | 660 | $16K | 9/15/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 1,260 | $31K | 9/8/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 471 | $11K | 8/11/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 1,260 | $23K | 6/25/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 2,520 | $46K | 6/24/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 8,584 | $167K | 6/16/2025 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 6/3/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 3,780 | $15K | 5/21/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 6,300 | $21K | 5/14/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 1,120 | $4K | 5/13/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 12,601 | $38K | 5/12/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 33,376 | $107K | 5/9/2025 | View on chart |
| PHAT | ▲ Buy | Open Market | 2,226 | $8K | 5/9/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 1,135 | $26K | 3/26/2025 | View on chart |
| NAMS | ▲ Buy | Open Market | 4,005 | $84K | 3/4/2025 | View on chart |
| PHAT | ▲ Buy | Grant | 10,500 | $0 | 5/23/2024 | View on chart |
| NAMS | ▲ Buy | Open Market | 8,429 | $181K | 3/26/2024 | View on chart |
| PHAT | ▲ Buy | Grant | 9,000 | $0 | 5/25/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
PHAT launches Phase 3 study for VOQUEZNA in GERD
Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.
PHAT launches Phase 3 study for VOQUEZNA in GERD. Phathom Pharmaceuticals has begun a Phase 3 trial of VOQUEZNA, a drug aimed at treating non‑erosive gastro‑esophageal reflux disease on an as‑needed basis. The study is a critical step toward regulatory approval and could expand the company’s product portfolio. The move follows earlier development phases and may influence investor perception of the company’s growth prospects.